← Compounds
Acarbose
off-label Rx · medium oversightFDA-approvedAlpha-glucosidase inhibition; post-prandial glucose
Overview
Alpha-glucosidase inhibitor; blunts post-prandial glucose. Used off-label for metabolic/longevity goals.
How it works
- Delays intestinal carbohydrate digestion
- ↓ post-prandial glucose
Dosing
25–100 mg with first bite of each main meal.
Oral50 mg standardrange —–100 mg· with meals
Cycling
- Continuous
Side effects
- Common
- Flatulence, GI (dose-related)
- Warnings
Verified citations
2 · PubMed-checked- Effects of alpha-glucosidase-inhibiting drugs on postprandial glucose and insulin: meta-analysis.clinicalPMID 33658478 ↗
- Clinical utility of acarbose, an alpha-glucosidase inhibitor in cardiometabolic disorders.reviewPMID 19275550 ↗
Reconstitution
Not applicable — this compound is oral. No vial reconstitution needed.
Used for
No condition evidence rows yet.
Legal / compounding
FDA-approved
- FDA
- Approved
Legal status is a hard gate: non-compoundable or delisted agents cannot be filled and are blocked from protocol export. Keep 503A status current.